BioCentury | Oct 24, 2016
Product Development
A new BEAT for AML
...IDH2-positive Ph III Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Samalizumab Anti-CD200 mAb Undisclosed NA Boehringer Ingelheim GmbH BI 836858...
...a total of 10. The first four agents are samalizumab, an anti-CD200 mAb from Alexion; BI 836858...
...IDH2) from Celgene and Agios Pharmaceuticals Inc. Patients with an IDH2 mutation will receive enasidenib. BI 836858...
...a total of 10. The first four agents are samalizumab, an anti-CD200 mAb from Alexion; BI 836858...
...IDH2) from Celgene and Agios Pharmaceuticals Inc. Patients with an IDH2 mutation will receive enasidenib. BI 836858...
